PureTech Health Gets Orphan Drug Designation for Deupirfenidone Lung Treatment

By Chris Wack

 

PureTech Health said the Food and Drug Administration and European Commission have granted orphan drug designation to deupirfenidone LYT-100 for the treatment of idiopathic pulmonary fibrosis, a rare, progressive and fatal lung disease.

The biotherapeutics company said that deupirfenidone is being advanced by Celea Therapeutics, an entity established by PureTech to lead its late stage development and potential commercialization.

Orphan drug designation is intended to support the development of therapies for rare diseases, defined as conditions affecting fewer than 200,000 people in the U.S. or fewer than five in 10,000 individuals in the European Union.

PureTech said Celea Therapeutics intends to finalize financing in the first half of 2026 to support the initiation of a Phase 3 trial in the first half of 2026. The trial will compare deupirfenidone 825 mg to pirfenidone 801 mg in a head-to-head study powered to test for superiority.

Based on feedback from the FDA and other global health authorities, PureTech believes that the results from this single Phase 3 trial could complete the data package required to support potential registration of deupirfenidone.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

February 19, 2026 13:30 ET (18:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center